Short Introduction
We include in this edition of the journal selected abstracts of the 2nd Annual Convention of the Cardio Renal Society of America: Cardio Renal Crisis: Global Epidemiology . We anticipate that selected abstracts from this meeting will be published annually following the meeting.
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Guest Editorial
As editors we are pleased to bring the proceedings of the 2nd Annual Convention of the Cardio Renal Society of America (CRSA) to clinicians. CRSA is a nonprofit community healthcare organization whose goal is to help prevent and manage heart and kidney disease through public and professional education and research. We aspire to be the foremost leader in identifying and raising awareness of the interconnections between heart and kidney disease, resulting in improved quality of life and survival.
The 1st Annual Convention of the Society was held in March 2013 in Phoenix, Ariz. The proceedings described in this issue are from the 2nd Annual Convention of CRSA. The CME portion of the CRSA convention began with the plenary session lunch presentation, which was attended together with participants in the Southwest Nephrology Conference. This course was designed to review the state of the art and current state of knowledge of cardiovascular disease (CVD) in patients with chronic kidney disease and renal function deterioration in subjects with CVD.
Cardiorenal syndrome (CRS) is defined as a pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction of one organ may induce acute or chronic dysfunction of the other. This relationship includes the vast array of interrelated derangements and, to stress, the bidirectional nature of heartkidney interactions. The members of the faculty described below are world renowned with expertise in their respective field, who were able to present a state-of-the-art content on each of the topics.
Upon completion of this course, participants were able to gain knowledge in the areas of:
(1) The global impact of CRS; (2) New staging classification of heart failure in ESRD; (3) Diabetes and its cardiorenal impact; (4) Novel biomarkers in acute kidney injury, and (5) Pathogenesis and treatment of CRS. Continuing education credit for physicians and physicians in training was planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Phoenix Children's Hospital and CRSA. Phoenix Children's Hospital is accredited by the ACCME to sponsor continuing medical education for physicians. Phoenix Children's Hospital designated this live activity for a maximum of 5 AMA PRA Category 1 Credit/s. A certificate of attendance was provided to nurse practitioners, nurses, patient care technicians and physician assistants at the end of the conference for use in documenting their contact hours of continuing education at this conference. Social workers received credit from Arizona Chapter of the National Association of Social Workers, and dietitians received certificate of attendance from the Academy of Nutrition and Dietetics. We announced a disclaimer that attendance at this course did not indicate nor guarantee competence or proficiency in the performance of any procedures, which may be discussed or taught in this course.
We hope that you are able to enjoy the publication of the abstracts of the Convention and recognize that cardiorenal disease is associated with significant comorbidity, hence, it behooves us to take a proactive role in the prevention of and aggressive intervention for this condition to improve the quality of life, decrease cost and enhance survival.
Krishnaswami Vijayaraghavan Bhupinder Singh The death rate for all US dialysis patients in 2011 was 198 per 1,000 patient-years; cardiac disease is the major cause of death in dialysis patients, accounting for 39% of all-cause mortality. 14% of cardiac deaths are attributed to acute myocardial infarction; 66% of cardiac deaths are sudden/ arrhythmic in etiology, or 26% of all-cause mortality. Factors impacting sudden cardiac death in ESRD patients include obstructive coronary artery disease, left ventricular hypertrophy, myocardial fibrosis, electrolyte shifts in hemodialysis patients, and autonomic dysfunction. From the decade spanning 1999-2009, there has been a progressive decline in cardiovascular death in US dialysis patients, including arrhythmic death. The initiation of hemodialysis is characterized by a marked increase in the rate of sudden cardiac death, particularly in the first three months after hemodialysis initiation.
CRSA Planning Committee
Modifiable risk factors contributing to the risk of increase in sudden cardiac death are 0 or 1.0 mEq/l potassium dialysate baths, as are calcium baths lower than 2.5 mEq/l. Risk stratification to identify dialysis patients at risk of sudden death include the use of cardiac biomarkers (e.g., cardiac troponin T) and assessment of left ventricular function.
The incidence of cardiac arrest in dialysis clinics has been reported to be between 3.8 and 7 per 100,000 hemodialysis runs. No clinical trials have been published assessing the efficacy and safety of implantable cardiovertor defibrillators for prevention of sudden death in dialysis patients. A newly proposed trial, WED-HED ( W earable E xternal D efibrillator in He mo d ialysis patients), is currently in the planning phase. The intent of WED-HED is to test the efficacy of wearable external defibrillators (a non-invasive intervention) to prevent sudden cardiac death in newly incident hemodialysis patients.
Novel Biomarkers of Kidney Injury in Cardio-Renal Syndrome

Chirag R. Parikh, MD, PhD
Yale University and Veterans Affairs Medical Center, New Haven, CT Renal dysfunction during heart failure is a serious -and unfortunately, frequent -blend of complications, known as Cardio-Renal syndrome (CRS). While the mechanisms underlying the interactions between the two organ systems and the ensuing damage have yet to be uncovered, this overlap has been appreciated to intensify the disease state and thus also deepens the need for therapeutic progress.
Evaluating renal impairment provides novel perspective to understand this condition; however, the current mainstay for kidney injury assessment and acute kidney injury (AKI) diagnosis is the use of serum creatinine (SCr) -a delayed, nonspecific marker. Changes in SCr can be caused by a variety of non-renal factors and may not represent true injury. Such complexities have been showcased in the field of CRS, in which several studies have demonstrated that SCr increases during therapeutic regimens may not be harmful and, in fact, even coincide with increased survival. These findings, along with the recent CRS treatment trial failures, stress the pressing need for a paradigm shift from dependence on SCr to developing disease-specific, early biomarkers of injury that can identify markers of structural damage before functional failure occurs.
Several small studies have already been conducted using novel biomarkers of AKI (urine NGAL, IL-18, KIM-1, serum NGAL) to assess structural damage in the nephron and outcomes in CRS. Though the studies have investigated a variety of outcomes, including worsening renal function, natriuresis, and diuresis, the most robust findings predicted outcomes of mortality and re-hospitalization.
Ultimately, the use of novel biomarkers in CRS hold tremendous potential to facilitate the identification of patients who will have worsening renal function, improve phenotyping of patients with CRS, and assist in both short-and longterm risk stratification and management of CRS patients.
Diabetes and Its Cardio-Renal Impact
Harold M. Szerlip, MD
University of North Texas, Fort Worth, TX
Fueled by the epidemic of obesity, the prevalence of diabetes is increasing. Over the last 20 years there has been a tripling of the number of persons with diabetes and this trend is expected to continue. Visceral obesity is an inflammatory state that results in insulin resistance and hyperglycemia. The micro-and macro-vascular effects of diabetes are well described. In 2012 the medical costs associated with diabetes were 176 billion dollars with an additional 69 billion dollars in lost productivity. Diabetes has long been known to be a coronary artery risk equivalent; it is also the leading cause of chronic kidney disease. Almost half the patients starting dialysis have diabetes and although the incidence of end-stage kidney disease secondary to diabetes appears to be plateauing, its prevalence continues to increase. Thirty percent of the Medicare expenditure for diabetes is for kidney disease. Diabetic kidney disease is usually associated with albuminuria. Albuminuria may regress or may progress to ever increasing levels. The greater the degree of albuminuria the faster the progression to end-stage kidney disease and the greater the cardiovascular risk. In fact recent data show that in diabetics without underlying kidney disease, as defined by either albuminuria or a decrease in GFR, the incidence of cardiovascular disease is not much greater than in the population without diabetes. This raises the possibility that the DOI: 10.1159/000365644 2nd Annual Convention of the Cardio Renal Society of America: Cardio Renal Crisis: Global Epidemiology www.karger.com/crm © 2014 S. Karger AG, Basel cause of both the cardiovascular disease and the kidney disease are manifestations of the underlying vasculopathy. Albuminuria is a powerful biomarker for cardiovascular disease. When compared to other biomarkers of kidney injury such as KIM-1 and IL-18, albuminuria is a better predictor of cardiovascular risk. Chronic inflammation induced by obesity, hyperglycemia and insulin resistance produces dysfunction of the vascular endothelium, which is manifested by both kidney and heart disease. Thus diabetes is a true cardiorenal syndrome.
Fibrosis in the Heart and Kidneys in the Pathogenesis of Chronic Cardio-Renal Syndromes
Peter A. McCullough, MD, MPH
Baylor College of Medicine, Dallas, TX
In recent years there has been considerable interest in cellular and tissue responses to injury that result in the deposition of extracellular matrix, collagen, elastic, and the histopathological development of fibrosis. In the myocardium, fibrosis results in many recognizable clinical features including PR interval prolongation, heart block, bundle branch block, left ventricular dyssynergy, anisotropy, atrial fibrillation, ventricular arrhythmias, systolic and diastolic dysfunction, heart failure and cardiac death. In the kidneys, fibrosis in the glomerulus leads to glomerular sclerosis and in the in inner cortex and medulla, tubulointerstitial fibrosis leads to a reduction in renal filtration function and rapidly progressive chronic kidney disease (CKD).
There are a great number of potential early mediators of cellular damage in response to events such as ischemia, neurohormonal activation, biomechanical stretch, and abnormal cell signaling. However, many studies suggest that interstitial cells in both organs including macrophages, T-lymphocytes, fibroblasts, and myofibroblasts have common communication systems that utilize galectin-3 and transforming growth factor-beta that result in upregulation and proliferation of fibroblasts and myofibroblasts which produce and secrete procollagen I. Procollagen I cross-links in the extracellular space to form mature collagen, which is a fundamental unit of organ fibrosis.
Future research is concentrating on the pathogenic mechanisms that turn on fibrosis and on therapeutic targets that can either prevent the activation of fibroblasts or limit their repair response to injury.
Multi-Organ Effects of Cardio-Renal Syndrome
Bhupinder Singh, MD, FASN, FNKF
Creighton University School of Medicine, Phoenix, AZ Renal dysfunction can have multi-system effects. With the ready availability of dialysis in the US, critically ill patients with acute kidney injury (AKI) are instead dying of extra-renal complications. There is abundance of epidemiologic data which confirms distant organ effects of AKI but mechanistic data is lacking. Various hypotheses have been proposed, including increased vascular permeability and increased level of inflammatory cytokines. In fact, the effects of acute kidney injury on other organ systems mimic the effects seen due to sepsis.
Chawla et al reported in 2013 that veterans with AKI alone have worse outcomes than those diagnosed with myocardial infarction (MI) in the absence of AKI. Those who developed AKI in the setting of MI had worse long term outcomes compared to AKI or MI alone. This suggests that development of AKI is associated with long term complications, likely due to effects on other organ systems. Experimental AKI can cause pulmonary changes, possibly mediated through increased vascular permeability leading to, or worsening acute lung injury (ALI). As seen in case of MI with AKI, development of AKI in the setting of ALI can increase mortality substantially. AKI also contributes to neurological changes. While underlying mechanisms are poorly understood, animal models have shown increased inflammatory markers and increased vascular permeability.
In summary, AKI can lead to molecular changes and organ dysfunction in heart, lung and brain. Detailed studies of inflammatory and transport pathways can reveal novel therapeutic targets and biomarkers of organ cross talk in critically ill patients with AKI.
New Staging Classification of Heart Failure in End-Stage Renal Disease
Lakhmir Chawla, MD George Washington Medical Center, Washington, DC Structural heart disease is highly prevalent in patients with chronic kidney disease requiring dialysis. 80-85% of end-stage renal disease (ESRD) patients are reported to have some form of cardiovascular disease (CVD). This observation has enormous clinical relevance, because the leading causes of death for ESRD patients are of CVD etiology, including heart failure, myocardial infarction, and sudden cardiac death.
The two systems most commonly used to classify the severity of heart failure are the New York Heart Association (NYHA) functional classification and the American Heart Association/American College of Cardiology (AHA/ACC) DOI: 10.1159/000365644 2nd Annual Convention of the Cardio Renal Society of America: Cardio Renal Crisis: Global Epidemiology www.karger.com/crm © 2014 S. Karger AG, Basel staging system. With rare exceptions, ESRD patients who do not receive renal replacement therapy (RRT) develop signs and symptoms of heart failure, including dyspnea and edema due to inability of the severely diseased kidneys to excrete sodium and water. Thus, by definition, nearly all ESRD patients develop a symptomatology consistent with heart failure if fluid removal by RRT is delayed. Neither the AHA/ACC heart failure staging nor the NYHA functional classification system identifies the variable symptomatology that ESRD patients experience depending upon whether evaluation occurs before or after fluid removal by RRT. Consequently, the incidence, severity, and outcomes of heart failure in ESRD patients are poorly characterized.
The 11th Acute Dialysis Quality Initiative has identified this issue as a critical unmet need for the proper evaluation and treatment of heart failure in patients with ESRD. We propose a classification schema based on patient-reported dyspnea assessed both pre-and post-ultrafiltration, in conjunction with echocardiography. The ADQI system allows for dyspnea assessment in a standardized fashion, and should improve communication amongst the caregivers of these patients. The ADQI group hypothesizes that this system will also be predictive of outcomes. There is a strong association between both acute and chronic dysfunction of the heart and kidneys with respect to morbidity and mortality. The complex inter-relationships of longitudinal changes in both organ systems has been difficult to describe and fully understand due to a lack of categorization of the common clinical scenarios where these phenomenon are encountered.
Current Treatment Options for the Management of Cardio-Renal Syndrome
Cardio-Renal Syndromes (CRS) have been subdivided into five types which represent clinical vignettes in which both the heart and the kidney are involved in bidirectional injury and dysfunction via a final common pathway of cell-tocell death and accelerated apoptosis mediated by oxidative stress. Types 1 and 2 involve acute and chronic cardiovascular disease (CVD) scenarios leading to acute kidney injury (AKI) or accelerated chronic kidney disease (CKD). Types 3 and 4 describe AKI and CKD, respectively, leading primarily to heart failure, although it is possible that acute coronary syndromes, stroke, and arrhythmias could be CVD outcomes in these forms of CRS. Finally, CRS type 5 describes a systemic insult to both heart and the kidneys, such as sepsis, where both organs are injured simultaneously in persons with previously normal heart and kidney function at baseline.
For type 1 CRS in the setting of acutely decompensated heart failure (ADHF), many novel therapies and clinical trials of strategies using conventional approaches have failed to show differential effects on hard clinical outcomes including rehospitalization, need for hemodialysis, or death. What has been learned from these trials in general has been that decompensated heart failure actually starts about two weeks before admission with a rise in intracardiac pressure and probably neurohormonal activation. Once hospitalized, ∼ 25% of ADHF develop type 1 CRS with a rise in serum creatinine ≥ 0.3 mg/ dl. Venous congestion, use of combined angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, and use of continuous loop diuretic infusions are associated with higher rates of type 1 CRS.
Therapy including vasodilators, inotropic agents, diuretics, and mechanical support need to be individualized based on the presences of ischemic heart disease, the hemodynamic evaluation, and renal filtration function. Novel therapies that are likely to succeed with probably demonstrate both cardiac and renal salutary effects on blood biomarkers in phase II, and hard clinical outcomes in phase III randomized trials.
